Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6799686 | 0.99 | HCAR2 (0.41) | HCAR2CYP2C9HSD17B1ESR1ESR2 | |
| SCHEMBL6798259 | 0.93 | HCAR2 (0.37) | HCAR2CYP2C9HSD17B1ESR1PDPK1 | |
| Bromide SCHEMBL6795275 | 0.92 | HCAR2 (0.37) | HCAR2CYP2C9HSD17B1ESR1PDPK1 | |
| Hydrochloric Acid SCHEMBL1656581 | 0.89 | HCAR2 (0.44) | HCAR2CYP2C9ESR1CYP2C8PDPK1 | |
| Hydrochloric Acid SCHEMBL6792819 | 0.81 | ESR1 (0.33) | HCAR2CYP2C9ESR1 | |
| Trifluoroacetic Acid SCHEMBL6786915 | 0.76 | ESR1 (0.33) | HCAR2CYP2C9ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL6792800 | 0.75 | HCAR2 (0.39) | HCAR2CYP2C9ESR1ESR2CDK2 | |
| Trifluoroacetic Acid SCHEMBL6787997 | 0.75 | ESR1 (0.31) | ESR1 | |
| Bromide SCHEMBL1658121 | 0.74 | PDPK1 (0.39) | HCAR2CYP2C9PDPK1CDK2 | |
| SCHEMBL6792318 | 0.73 | PDPK1 (0.35) | HCAR2PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HCAR2 1767/4885CYP2C9 1505/4885HSD17B1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.